Relaxin for treatment of acute heart failure: Making the case for treating targeted patient profiles

Current Heart Failure Reports

Volumn 10, Issue 3, 2013, Pages 198-203

  Hernandez Montfort, Jaime A ^a   Arora, Sonali ^a   Slawsky, Mara T ^a  

^a TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Acute heart failure; Blood pressure; Clinical trials; Relaxin; Vasodilator

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BIOLOGICAL MARKER; DIURETIC AGENT; FUROSEMIDE; GLYCERYL TRINITRATE; NITROPRUSSIDE SODIUM; PLACEBO; RELAXIN; VASODILATOR AGENT;

ACUTE HEART FAILURE; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BLOOD PRESSURE REGULATION; DIURETIC THERAPY; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG EFFICACY; DYSPNEA; HUMAN; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); SYSTOLIC BLOOD PRESSURE; VISUAL ANALOG SCALE;

ACUTE DISEASE; BIOLOGICAL MARKERS; DRUG MONITORING; HEART FAILURE; HUMANS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RELAXIN; TREATMENT OUTCOME; VASODILATOR AGENTS;

EID: 84881478350     PISSN: 15469530     EISSN: 15469549     Source Type: Journal    
DOI: 10.1007/s11897-013-0148-6     Document Type: Article

References (33)

1. Fonarow GC, Abraham WT, Albert NM, et al. Influence of a performance-improvement initiative on quality of care for patients hospitalized with heart failure: results of the Organized Program to Initiate Lifesaving Treatment in Hospitalized Patients with Heart Failure (OPTIMIZE-HF). Arch Intern Med. 2007;167:1493-502.
2. Solomon SD, Dobson J, Pocock S, et al. Influence of nonfatal hospitalization for heart failure on subsequent mortality in patients with chronic heart failure. Circulation. 2007;116:1482-7.
3. Gheorghiade M, Pang PS. Acute heart failure syndromes. J Am Coll Cardiol. 2009;53:557-73.
4. McMurray JJ, Adamopoulos S, Anker SD, et al. ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: the Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. Eur Heart J. 2012;33:1787-847.
5. Laribi S, Aouba A, Nikolaou M, et al. Trends in death attributed to heart failure over the past two decades in Europe. Eur J Heart Fail. 2012;14:234-9.
6. Cotter G, Metra M, Milo-Cotter O, Dittrich HC, Gheorghiade M. Fluid overload in acute heart failure - re-distribution and other mechanisms beyond fluid accumulation. Eur J Heart Fail. 2008;10:165-9.
7. Gheorghiade M, Follath F, Ponikowski P, et al. Assessing and treating congestion in acute heart failure: a scientific statement from the acute heart failure committee of the Heart Failure Association of the European Society of Cardiology and endorsed by the European Society of Intensive Care Medicine. Eur J Heart Fail. 2010;12:423-33.
8. Metra M, Cotter G, Gheorghiade M, Dei Cas L, Voors AA. The role of the kidney in heart failure. Eur Heart J. 2012;33:2135-42.
9. Gupta D, Georgiopoulou VV, Kalogeropoulos AP, et al. Dietary sodium intake in heart failure. Circulation. 2012;126:479-85.
10. Felker MG, Lee KL, Bull DA, et al. Diuretic strategies in patients with acute decompensated heart failure. N Engl J Med. 2011;364:797-805.
11. O'Connor CM, Starling RC, Hernandez AF, et al. Effect of nesiritide in patients with acute decompensated heart failure. N Engl J Med. 2011;365:32-43.
12. Cuffe SM, Califf RM, Adams KF, et al. Short-term intravenous milrinone for acute exacerbation of chronic heart failure. J Am Med Assoc. 2002;287:1541-7.
13. Cleland JGF, Freemantle N, Coletta AP, Clark AL. Clinical trials update from the American Heart Association: REPAIR-AMI, ASTAMI, JELIS, MEGA, REVIVE-II, SURVIVE, and PROACTIVE. Eur J Heart Fail. 2006;8:105-10.
14. Cotter G, Voors AA, Davison BD. Acute heart failure clinical drug development: From planning to proof of activity to phase III. Cardiology. 2010;116:292-301.
15. Abraham WT, Kirkwood AF, Fonarow GC, et al. In-hospital mortality in patients with acute decompensated heart failure requiring intravenous vasoactive medications. An analysis from the Acute Decompensated Heart Failure National Registry (ADHERE). J Am Coll Cardiol. 2005;46:57-64.
16. Gheorghiade M, Braunwald E. A proposed model for initial assessment and management of acute heart failure syndromes. JAMA. 2011;305:1702-3.
17. •• Gheorghiade M, Pang P, O'Connor CM, et al. Clinical development of pharmacologic agents for acute heart failure syndromes: A proposal for a mechanistic translational phase. Am Heart J. 2012;163:149-55. This article proposes insertion of a translational phase trial during clinical development of a pharmacologic agent to test the mechanistic hypothesis in a small, clinically "homogeneous" group of patients before proceeding to a phase II trial.
18. • Marti CN, Gheorghiade M, Kalogeropoulos AP, et al. Endothelial dysfunction, arterial stiffness and heart failure. J Am Coll Cardiol. 2012;60:1455-69. This article focuses on the importance of endothelial function and vascular stiffness as targets for investigation of therapies in acute heart failure.
19. Cotter G, Metzkor E, Kaluski E, Faigenberg Z, et al. Randomized trial of high-dose isosorbide dinitrate plus low-dose furosemide versus high-dose furosemide plus low-dose isosorbide dinitrate in severe pulmonary edema. Lancet. 1998;351:389-93.
20. Teichman SL, Unemori E, Dschietzig T, et al. Relaxin, a pleiotropic vasodilator for the treatment of heart failure. Heart Fail Rev. 2009;14:321-9.
21. Conrad KP. Maternal vasodilation in pregnancy: The emerging role of relaxin. Am J Physiol Regul Integr Comp Physiol. 2011;301:R267-75.
22. • Teichman SL, Unemori E, Teerlink JR. Relaxin: Review of biology and potential in treating heart failure. Curr Heart Fail Rep. 2010;7:75-82. This article provides an overview of relaxin biology and physiologic effects of relaxin in preclinical and clinical studies.
23. Dschietzig T, Teichman S, Unemori E, et al. Intravenous recombinant human relaxin in compensated heart failure: a safety, tolerability, and pharmacodynamic trial. J Card Fail. 2009;15:182-90.
24. Teerlink JR, Metra M, Felker MG, et al. Relaxin for the treatment of patients with acute heart failure (pre-RELAX-AHF): A multicentre, randomized, placebo-controlled, parallel-group, dose-finding phase IIb study. Lancet. 2009;373:1429-39.
25. Teerlink JR, Cotter G, Davison BA, et al. Serelaxin, recombinant human relaxin-2, for treatment of acute heart failure (RELAX-AHF): A randomized, placebo-controlled trial. Lancet. 2013;381:29-39.
26. • Schwartzenberg S, Redfield MM, From AM, et al. Effects of vasodilation in heart failure with preserved or reduced ejection fraction implications of distinct pathophysiologies on response to therapy. J Am Coll Cardiol. 2012;59:442-51. This study, which examined the effects of nitroprusside in distinct heart failure profiles, emphasizes the importance of developing targeted heart failure therapies.
27. Metra M, Cotter G, Davison BA, et al. Effect of serelaxin on cardiac, renal, and hepatic biomarkers in the relaxin in acute heart failure (RELAX-AHF) development program. J Am Coll Cardiol. 2013;61:196-206.
28. Effects of tezosentan on symptoms and clinical outcomes in patients with acute heart failure: the VERITAS randomized controlled trials. JAMA 2007;298:2009-2019.
29. O'Connor CM, Fiuzat M, Swedberg K, et al. Influence of global region on outcomes in heart failure beta-blocker trials. J Am Coll Cardiol. 2011;58:915-22.
30. Cotter G, Felker GM, Adams KF, et al. The pathophysiology of acute heart failure-is it all about fluid accumulation? Am Heart J. 2008;155:9-18.
31. Colombo PC, Onat D, Sabbah HN. Acute heart failure as "acute endothelitis"-interaction of fluid overload and endothelial dysfunction. Eur J Heart Fail. 2008;10:170-5.
32. • Cotter G, Voors AA, Davison BD. Acute heart failure clinical drug development: from planning to proof of activity to phase III. Cardiology. 2010;116:292-301. This article compared multiple clinical AHF trials and demonstrated a high degree of heterogeneity in patient characteristics and outcome measures.
33. • Collins SP, Lindsell CJ, Pang PS, et al. Bayesian adaptive trial design in acute heart failure syndromes: moving beyond the mega trial. Am Heart J. 2012;164:138-45. This article proposes an AHF clinical trial design that is based on patient phenotypes.